(603811)"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603811 · · 12 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information provided, with the board of directors taking legal responsibility for its contents. Key financial data includes revenue and net profit figures, which reflect changes compared to the previous year. The report also outlines the company's total assets and shareholders' equity as of the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Chengyi Pharmaceutical Co. Ltd. on 6ix
Earlier from Zhejiang Chengyi Pharmaceutical
- (603811)"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Results of Shareholding Reduction by Director and Senior Executive
- Announcement on Results of Shareholding Reduction by Senior Executive
- Announcement on a Subsidiary's Receipt of Drug GMP Compliance Inspection Results
- Announcement on Outline of the 2026 Semi-annual Performance Briefing
- Announcement on Satisfaction of Unlocking Conditions for the 1st Unlocking Period under the 2025 Employee Stock Ownership Plan
Follow Zhejiang Chengyi Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Chengyi Pharmaceutical